调强放疗时代鼻咽癌的竞争风险列线图:基于大数据智能平台的分析
研究利用机构大数据智能平台纳入2009—2014年接受调强放疗的7251例鼻咽癌患者,基于Fine-Gray竞争风险分析建立列线图。队列5年鼻咽癌特异死亡率为13.1%、其他原因特异死亡率为1.2%;年龄≥65岁或合并严重共病者5年其他原因特异死亡率升高。研究呈现首个量化竞争风险的预后列线图,可能有助于个体化治疗。
要点
- 7251例调强放疗鼻咽癌患者5年鼻咽癌特异死亡率为13.1%,其他原因特异死亡率为1.2%。
- 年龄≥65岁者5年其他原因特异死亡率为5.5%,合并严重共病者为4.3%。
- 年龄55—64岁和其他原因死亡SHR为2.70,≥65岁为5.78;CCI 1分和≥2分SHR分别为2.33和2.58。
核心结论
- 在老年患者和合并共病的患者中,其他原因特异死亡是鼻咽癌特异死亡的重要竞争事件。
- 研究呈现首个量化竞争风险的预后列线图,可能有助于个体化治疗。
研究设计与样本
- 利用机构大数据智能平台识别2009—2014年接受调强放疗的7251例鼻咽癌患者。
- 基于Fine和Gray竞争风险分析建立列线图。
主要发现
- 队列5年鼻咽癌特异死亡率为13.1%,其他原因特异死亡率为1.2%。
- 年龄≥65岁患者5年其他原因特异死亡率为5.5%,合并严重共病患者为4.3%。
- 年龄55—64岁患者其他原因死亡SHR为2.70(95%CI 1.64—4.4,P<.001),≥65岁为5.78(95%CI 3.32—10.08,P<.001)。
- CCI 1分患者其他原因死亡SHR为2.33(95%CI 1.46—3.71,P<.001),CCI≥2分为2.58(95%CI 1.16—5.73,P=.020)。
- 鼻咽癌特异死亡模型纳入年龄、性别、组织学类型、肿瘤和淋巴结分期、血浆EBV-DNA水平、LDH水平和CRP水平,c-index=0.743;其他原因死亡模型纳入年龄、CCI、白蛋白水平和CRP水平,c-index=0.793。
关键数值与推荐
- 年龄55—64岁和其他原因死亡SHR为2.70(95%CI 1.64—4.4,P<.001),≥65岁为5.78(95%CI 3.32—10.08,P<.001)。
- CCI 1分和其他原因死亡SHR为2.33(95%CI 1.46—3.71,P<.001),CCI≥2分为2.58(95%CI 1.16—5.73,P=.020)。
- 鼻咽癌特异死亡列线图c-index=0.743;其他原因死亡列线图c-index=0.793。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Lacking quantitative evaluations of competing risk data of nasopharyngeal carcinoma (NPC), we aimed to evaluate the probability of NPC- and other cause-specific mortality (NPC-SM; OCSM) and develop competing risk nomograms to quantify survival differences. MATERIAL AND METHOD: Using the institutional big-data intelligence platform, 7251 NPC patients undergoing intensity-modulated radiotherapy between 2009-2014 were identified to establish nomograms based on Fine and Gray's competing risk analysis. RESULTS: The 5-year NPC-SM and OCSM of the cohort were 13.1% and 1.2%, respectively, and elevated 5-year OCSMs were observed in patients aged ≥65 years (5.5%) or with severe comorbidities (4.3%). Age was most predictive of OCSM: patients aged 55-64 and ≥65 years exhibited subdistribution hazard ratios (SHRs) of 2.70 (95% confidence interval [CI], 1.64-4.4; P < .001) and 5.78 (95% CI, 3.32-10.08; P < .001), respectively. Comorbidity measured using the Charlson Comorbidity Index (CCI) was also strongly predictive of OCSM: patients with CCI scores of 1 and ≥2 exhibited SHRs of 2.33 (95% CI, 1.46-3.71; P < .001) and 2.58 (95% CI, 1.16-5.73; P = .020), respectively. All validated factors were integrated into the competing nomograms: age, sex, histology type, tumor and node stages, plasma Epstein-Barr virus-DNA level, lactate dehydrogenase level, and C-reactive protein (CRP) level into the NPC-SM model (concordance [c]-index = 0.743); and age, CCI, Albumin level, and CRP level into the OCSM model (c-index = 0.793). CONCLUSION: OCSM represents a significant competing event for NPC-SM in elderly patients and patients with comorbidities. We present the first prognostic nomograms to quantify competing risks, which may help to tailor individualized treatment.
引用
- Huang XD, Zhou GQ, Lv JW, et al. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis. Radiother Oncol. 2018. PMID: 30270098. doi:10.1016/j.radonc.2018.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。